论文部分内容阅读
目的 :探讨分析美沙拉嗪缓释颗粒(艾迪沙)以及柳氮磺吡啶治疗活动期轻、中度溃疡性结肠炎的临床疗效和不良反应。方法 :选取我院2013年3月至2015年3月期间接收治疗的120例活动期轻、中度溃疡性结肠炎患者作为研究分析对象,将所选患者按入院单双号分为对照组和观察组,每组各60例,对照组采用柳氮磺吡啶进行治疗,观察组患者采用美沙拉嗪缓释颗粒进行治疗,比较两组患者临床治疗疗效和不良反应状况。结果 :比较两组患者治疗总疗效,观察组(95%)明显高于对照组(81.67%),且数据存在一定差异,具有统计学意义(P<0.05)。比较两组患者不良反应总发生率,观察组(6.67%)明显低于对照组(20%),且数据存在一定差异,具有统计学意义(P<0.05)。结论 :临床中,治疗活动期轻、中度溃疡性结肠炎疾病可采用美沙拉嗪缓释颗粒进行治疗,此治疗方式可提高患者治疗疗效,与柳氮磺吡啶治疗疗效进行比较,前者更具有优势,且安全可靠,临床应用价值大。
Objective: To investigate the clinical efficacy and adverse reactions of mesalazine sustained-release granules (Addisais) and sulfasalazine for active and mild ulcerative colitis. Methods: A total of 120 patients with mild to moderate ulcerative colitis who received active treatment from March 2013 to March 2015 in our hospital were selected as research objects. The patients were divided into control group The observation group, 60 cases in each group. The control group was treated with sulfasalazine. The patients in the observation group were treated with mesalazine sustained-release granules for treatment. The clinical efficacy and adverse reactions of the two groups were compared. Results: The total curative effect was compared between the two groups. The observation group (95%) was significantly higher than that of the control group (81.67%). There was a statistically significant difference between the two groups (P <0.05). The total incidence of adverse reactions was compared between the two groups. The observation group (6.67%) was significantly lower than the control group (20%), and the data there was a certain difference (P <0.05). Conclusions: In clinical practice, the treatment of mild and moderate ulcerative colitis disease can be treated with mesalazine sustained-release particles, this treatment can improve the efficacy of treatment, compared with the efficacy of sulfasalazine treatment, the former has more Advantages, and safe, reliable, clinical application of great value.